Abstract
In patients with systemic sclerosis (SSc) treatment-related mortality after autologous stem cell transplantation (ASCT) appears to be increased as compared to patients with hematological malignancies. In our phase I/II study on ASCT in autoimmune diseases a patient with SSc died on day 2 after ASCT. Here we report the results of the autopsy which revealed advanced pulmonary and cardiac fibrosis as the most probable cause of death. In spite of detailed technical examination before enrollment, the cardiopulmonary function tests did not reflect the advanced stage of the disease. We conclude that in selected patients with SSc, biopsies should be performed to reduce mortality after ASCT. Bone Marrow Transplantation (2001) 27, 657–658.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Tyndall A, Gratwohl A . Immune ablation and stem-cell therapy in autoimmune disease. Clinical experience Arthr Res 2000 2: 276–280
Rosen O, Thiel A, Massenkeil G et al. Autologous stem cell transplantation in refractory autoimmune diseases after in vivo immunoablation and ex vivo depletion of mononuclear cells Arthr Res 2000 2: 327–336
Tyndall A, Gratwohl A . Blood and marrow stem cell transplants in autoimmune disease. A consensus report written on behalf of the European League Against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT) Br J Rheumatol 1997 36: 390–392
Appelbaum F, Strauchen JA, Graw RG Jr et al. Acute lethal carditis caused by high-dose combination chemotherapy. A unique clinical and pathological entity Lancet 1976 1: 58–62
Buja LM, Ferrans VJ, Graw RG Jr . Cardiac pathologic findings in patients treated with bone marrow transplantation Hum Pathol 1976 7: 17–45
Kumar S, Gupta RK, Bhake AS, Samal N . Cardiotoxic effects of high doses of cyclophosphamide in albino rats Arch Pharmaco Ther 1992 319: 58–65
Acknowledgements
The authors are grateful to the nurses and the staff of the BMT Unit of the University Hospital Charité for the excellent care provided to our patients.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rosen, O., Massenkeil, G., Hiepe, F. et al. Cardiac death after autologous stem cell transplantation (ASCT) for treatment of systemic sclerosis (SSc): no evidence for cyclophosphamide-induced cardiomyopathy. Bone Marrow Transplant 27, 657–658 (2001). https://doi.org/10.1038/sj.bmt.1702829
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1702829
Keywords
This article is cited by
-
Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis
Bone Marrow Transplantation (2004)
-
Apoptosis contributes to cyclophosphamide-induced cardiomyopathy
Bone Marrow Transplantation (2002)